Free Trial

XOMA Royalty (NASDAQ:XOMA) Upgraded by Zacks Research to "Strong-Buy" Rating

XOMA Royalty logo with Medical background

Key Points

  • XOMA Royalty was upgraded to a Strong-Buy rating by Zacks Research, reflecting increased confidence in the stock's performance.
  • The company reported $0.48 earnings per share for the recent quarterly earnings, surpassing analyst expectations significantly.
  • Institutional investors own approximately 95.92% of XOMA Royalty's stock, indicating strong institutional interest and support for the company.
  • MarketBeat previews top five stocks to own in November.

Zacks Research upgraded shares of XOMA Royalty (NASDAQ:XOMA - Free Report) from a hold rating to a strong-buy rating in a research note released on Wednesday, September 10th,Zacks.com reports.

Several other brokerages have also recently issued reports on XOMA. HC Wainwright reiterated a "buy" rating and set a $104.00 price target on shares of XOMA Royalty in a research report on Wednesday, May 28th. Wall Street Zen upgraded XOMA Royalty from a "hold" rating to a "buy" rating in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company's stock. According to MarketBeat.com, XOMA Royalty has a consensus rating of "Buy" and an average target price of $69.50.

Check Out Our Latest Research Report on XOMA

XOMA Royalty Trading Up 1.8%

Shares of XOMA traded up $0.66 during mid-day trading on Wednesday, hitting $37.75. 17,525 shares of the company's stock traded hands, compared to its average volume of 44,914. The company has a quick ratio of 4.88, a current ratio of 4.88 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $456.40 million, a P/E ratio of -24.35 and a beta of 0.99. The business's 50-day moving average price is $30.35 and its 200-day moving average price is $25.76. XOMA Royalty has a 1 year low of $18.35 and a 1 year high of $38.34.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.60. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. The business had revenue of $13.13 million for the quarter, compared to analysts' expectations of $9.39 million. As a group, sell-side analysts forecast that XOMA Royalty will post -1.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC lifted its stake in shares of XOMA Royalty by 1,063.8% in the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 1,585 shares during the period. Tower Research Capital LLC TRC raised its position in XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 1,523 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company's stock worth $112,000 after acquiring an additional 543 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of XOMA Royalty during the 2nd quarter valued at $116,000. Finally, Deutsche Bank AG grew its position in shares of XOMA Royalty by 5,087.9% during the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 6,309 shares during the period. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Royalty Company Profile

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

Recommended Stories

Should You Invest $1,000 in XOMA Royalty Right Now?

Before you consider XOMA Royalty, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XOMA Royalty wasn't on the list.

While XOMA Royalty currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.